March in Spring: Highlights from EClinCloud's Recent Events

Source: EClinCloud. Author: EClinCloud.
As spring began in March, EClinCloud continued to pursue its mission of "bringing effective treatments to patients through scientific and technological innovation," presenting its digital solutions at major industry events and bringing new momentum to the clinical research industry through innovative technology.
"Beginning with the End in Mind: Empowering More Precise Clinical Outcome Assessment (COA) Through Digitalization and Intelligence"

February 29 · Shenzhen
First Stop of the 2024 R&G PharmaStudies Campus Tour
Qin Long, Founder and CEO of EClinCloud
At the event, Dr. Qin Long shared trends and advantages in clinical trial digitalization, highlighting the application of eCOA: compared with traditional COA, eCOA brings significant benefits to data collection in clinical research, making the collected data more complete, accurate, timely, and compliant.
He also shared EClinCloud's case studies, such as establishing an electronic trial master file (eTMF) management system for innovative pharmaceutical companies and major international CROs, and how eCOA supported the approval of a Phase III COVID-19 clinical trial.

"Enabling Patient-Centered Clinical Trials with eCOA"

March 7 · Chengdu
7th Chengdu Biopharmaceutical Innovators Summit
Qin Long, Founder and CEO of EClinCloud
Dr. Qin Long attended the "Patient-Centered" Clinical Trials sub-forum, where he and fellow experts presented on topics including regulations and trends in patient-centered clinical trials, patient-centered statistical design for innovative drugs, the application of technologies such as eCOA, clinical trial operations, and the clinical development of topical drugs.
Dr. Qin Long emphasized transforming clinical trials with technology, noting that the application of eCOA aligns with domestic and international regulatory and policy trends, delivers substantial value to subjects, investigators, sponsors, and auditors, and significantly improves completeness, accuracy, and compliance while reducing costs and increasing efficiency.
Notably, the "Survey Report on Patient-Centered Clinical Trials," in which Dr. Qin Long, Founder and CEO of EClinCloud, and Su Quanyu, Chief Commercial Officer of EClinCloud, participated as research team members, was officially released at the conference. Initiated by the Center for Pharmaceutical Policy and Evaluation Research at the School of Pharmacy, Chongqing Medical University, the survey offers valuable recommendations from the patient, industry, and societal perspectives.

Upcoming Event Preview

EClinCloud is a technology company focused on clinical R&D, providing an integrated, interoperable cloud platform for clinical trials (including various technology products and solutions such as eCOA, CTMS, eTMF, EDC, RTSM, and RM, as well as services within those solutions including scale design, scale copyright management, linguistic validation, rater training, and data quality analysis) along with clinical trial endpoint assessment technologies across therapeutic areas (including central nervous system, ophthalmology, and others). Combining cutting-edge technology with life data, it builds a globally leading, patient-centered SaaS cloud platform for clinical evidence support, helping domestic and international pharmaceutical companies and research institutions improve R&D efficiency, accelerate the market launch of drugs and medical devices, and benefit countless patients.



